The current status of human cancer vaccines

References

• CSATARTY LK, ECKHARDT S, BUKOSZA I, CZEGLEDI F, FENYVESI C, GERGILY P, BODEY B: Attenuated veteri-mary virus vaccine for the treatment of cancer. Cancer Detection and Prevention (1993) 17:619.
   PubMedGoogle Scholar
• BYSTRYN JC: Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens. Immunology (1978) 120:96–101.
   Web of Science ®Google Scholar
• This paper provides the preclinical justification in a murine model for therapeutic vaccination against melanoma.
   Google Scholar
• MORTON DL, FOSHAG LJ, HOON DSB: Prolongation of survival in metastatic melanoma after active specific inununotherapy with a new polyvalent melanoma vac-cine. Annals of Surgery (1992) 216(4):463–482.
   PubMed Web of Science ®Google Scholar
• HOON DSB, HAYASHI Y, MORISAKI T, ETAL: Interleukin-4 plus tumor necrosis factor a augments the antigenidty of melanoma cells. Cancer Irnmunol. Immunotherapy (1993) 37(6):378–384.
   PubMedGoogle Scholar
• HAYASHI Y, HOON DSB, FOSHAG, ET AL.: A preclinical model to assess the antigenicity of an IILA-A2 mela-noma cell vaccine. Cancer (1993) 72(3):750–759.
   Google Scholar
• MITCHELL MS, HAREL W, GROSHEN S: Assodation of HLAphenotype with response to active specific immuno-therapy of melanoma. J. Clin. Oncol. (1992) 10(7):1158–1164.
   PubMed Web of Science ®Google Scholar
• HERSEY P, EDWARDS A, D'ALESSANDRO G, MCCARTHY WH, MILTON, GW: Evidence that treatment with vacdnla melanoma cell lysates (VMCL) may improve survival of patients with stage LI melanoma. Cancer Immunot Im-munotherapy (1987) 25:257–265.
   PubMedGoogle Scholar
• HERSEY P, WERKMAN H, EDWARDS AE: Western blot analysis of serological responses following immuniza-tion with vaccinia viral lysates of melanoma cells. Int. J. Cancer (1990) 46(4):612–617.
   PubMed Web of Science ®Google Scholar
• BYSTRYN J-C, ORATZ R, ROSES D: Relationship between Immune responses to melanoma vaccine immuniza-tion and clinical outcome in stage II malignant mela-noma. Cancer (1992) 69(5):1157–1164.
   PubMed Web of Science ®Google Scholar
• BYSTRYN J-C, HENN M, LI LET AL.: Identification of Immunogenic human melanoma antigens in a polyva-lent melanoma vaccine. Cancer Res. (1992) 52(21):5948–5953.
   Google Scholar
• BERD D, MAGUIRE HC, MCCUE P, ET AL: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 pa-tients. J. Clin. Oncol. (1990) 8(11):1858–1867.
   PubMed Web of Science ®Google Scholar
• FUJIWARA H, AOKI H, YOSHIOKA T, TOMITA S, IKEGAMI R, HAMAOKA T: Establishment of a tumor specific im-munotherapy model utili7ing TNP-reactive helper cell activity and its application to the autochthonous tumor system. J. Immunol. (1984) 133:509–514.
   PubMed Web of Science ®Google Scholar
• FLOOD PM, SCHREIBER H, RON Y: Protective immunityto progressive tumors can be induced by antigen pre-sented on regressor tu.mors. J. Immunol. (1987) 138:3573–3579.
   PubMed Web of Science ®Google Scholar
• BERD D, MURPHY G, MAGUIRE HC, ET AL.: Immunization with haptenized, autologous tumor cells induces in-flammation of human melanoma metastases. Cancer Res. (1991) 51(10): 2731–2734.
   Google Scholar
• Describes novel approach to increase itnmunogenicity of autologous melanoma cell.
   Google Scholar
• LIVINGSTON PO, WANG GYC, ADLURI S, ETAL.: Improvedsurvival in stage M melanoma patients with GM2 anti-bodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. (1994) 12(5):1036–1044.
   Google Scholar
• HELLING F, SHANG A, CALVES M: GD3 vaccines for melanoma: Superior iffununogenicity of keyhole lim-pet hemocyanin conjugate vaccines. Cancer Res. (1994) 54:197–203.
   PubMed Web of Science ®Google Scholar
• COHEN AM, SHANK B, FRIEDMAN MA: Colorectal Cancer. In: Cancer Principles And Practice Of Oncology. Devita Jr, VT, Hellman S, Rosenberg SA (Eds). Third ed. Philadelphia. JB Lippincott (1989):895–964.
   Google Scholar
• HOOVER HC, BRANDHORST JS, PETERS LC, ET AL.: Adju-vant active specific immunotherapy for human colorec-tal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. j Clin. Oncol. (1993) 11(3):390–399.
   Google Scholar
• HASPEL MV, MCCABE RP, POMATO N, ET AL.: Coming fullcircle in the im.munotherapy of colorectal cancer: Vac-cination with autologous tumor cells - to human mono-clonal antibodies - to development and application of a generic tumor vaccine. In: Human Tumor Antigens and Specific Tumor Therapy. Alan R Liss, Inc. (1989):335–344.
   Google Scholar
• RANSOM JH, PELLE BA, HUBERS H, ET AL.: Identificationof colon-tumor-associated antigens by T-cell lines de-rived from tumor-infiltrating lymphocytes and periph-eral blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus calmette-guerin vac-cine. Mt. J. Cancer (1993) 54:734–740.
   Google Scholar
• HASPEL MV, MCCABLE RP, POMATO N, JANESCH N, KNOWLTON JV, PETERS LC, HOOVER JR. HC, HANNA JR. MG: Generation of tumor cell-reactive human mono-clonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma pa-tients. Cancer Res. (1985) 45:3951–3955.
   Google Scholar
• RANSOM JH, PELLE B, HANNA MG: Expression of class IImajor histocompatibility complex molecules correlates with human color tumor vaccine efficacy. Cancer Res. (1992) 52:3460–3466.
   PubMed Web of Science ®Google Scholar
• BLOEMENA E, GALL H, RANSOM JH, ET AL.: Delayed-typehypersensitivity reactions to tumor-associated antigens In colon carcinoma patients immunized with an autolo-gous tumor cell/bacillus calmette-guerin vaccine. Can-cer Res. (1993) 53:456–459.
   Google Scholar
• SCHALG P, MANASTERSKI M, GERNETH T, ET Al.: Activespecific Ircununotherapy with Newcastle-disease-virus-modified autologous tumor cell following resection of liver metastases in colorectal cancer. Cancer Immunol. Immunother. (1992) 35:325–330.
   Google Scholar
• SCHIRRMACHER V, HEICAPPEL R: Prevention of metas-tatic spread by post operative immunotherapy with virally modified autologous tumor cells. II Estab-lishment of specific systemic anti-tumor immunity. Gun. Exp. Metastasis (1987) 5:147–156.
   Google Scholar
• BRAY J, MACLEAN GD, RUSEL RJ, MCPHERSON TA: De-creased levels of circulation lytic anti-Tin the serum of patients with metastatic gastrointestinal cancer: a cor-relation with disease burden. Clin. Exp. Immunol. (1982) 47:176–182.
   PubMed Web of Science ®Google Scholar
• SPRINGER GF: T and Tn, general carcinoma autoan-tigens. Science (Washington DC), (1984) 224:1198–1206.
   PubMed Web of Science ®Google Scholar
• SINGHAI A, FOHN M, HAKONRORE: Induction of a n-ace-tylgalactosamine-0-serine/threonine (Tn) antigen me-diated cellular immune response for active immunotherapy in mice. CancerRes. (1991) 51:1406–1411.
   Google Scholar
• FIAKLOW P, KLEIN JE, KLEIN G, ET AL.: Immunoglobulin and glucose 6 phosphate dehydrogenase as markers of cellular origin in Burldtt's lymphoma. J. Exp. Med. (1973) 138:89.
   Google Scholar
• SALMON SE, SELIGMANN M: B cell neoplasia in man.Lancet (1974) 23:1230.
   Google Scholar
• PREUD'HOMME JL, SELIGMANN M: Surface bound inunu-nog,lobulin as a cell marker in human lymphoprolifera-tive diseases. Blood (1972) 40:777.
   PubMed Web of Science ®Google Scholar
• STEVENSON GT, STEVENSON FK: Antibody to molecu-larly defined antigen confined to a tumor cell surface. Nature (1975) 254:714..
   PubMed Web of Science ®Google Scholar
• SIRISINHA S, EISEN HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma protein. Proc. Natl. Acad. Sci. USA (1971) 68:3130.
   PubMed Web of Science ®Google Scholar
• This and reference 34 are the key papers providing the preclinical rationale in animal models for vaccination against tumour idiotype.
   Google Scholar
• LYNCH RG, CRAFF RJ, SIRISINHA S, ET AL.: Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA (1972) 69:1540.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI D, ET AL.: Induc-tion of immune responses in patients with B cell lym-phoma against the surface immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. (1992) 327:1209.
   Google Scholar
• First report of vaccination against tumour idiotype in nine human lymphoma patients.
   Google Scholar
• BOGEN B, MALISSEN B, HAAS W: Idiotype-specific T-cell clones that recognize syngeneic immunoglobulin frag-ments in the context of class II molecules. Eur. J. Immunol. (1986) 16:1373.
   PubMed Web of Science ®Google Scholar
• WATERS SJ, BONA CA: Characterization of a T-cell done recognizing idiotypes as tumor-associated antigens. Cell. Immunol. (1988) 111:87.
   PubMed Web of Science ®Google Scholar
• WRIGHT A, LEE JE, LINK MP, ET AL.: Cytotoxic T lympho-cytes specific for self tumor immunoglobulin express T-celi receptor 8 chain. J. E. Med. (1989) 169:1557.
   Google Scholar
• WILSON A, GEORGE AJT, KING CA, ET AL.: Recognition of a B cell lymphoma by anti-idiotypic T-cells. J. Immu-nol. (1990) 145:3937.
   Google Scholar
• WEISS S, BOGEN B: MHC class-II-restricted presentation of intracellular antigen. Cell (1991) 64:767.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI D, GHOSH SK: Induction of syngenek T lymphocytes against a B cell tumor. Cell. Immunol. (1992) 144:443.
   PubMed Web of Science ®Google Scholar
• CAO W, MYERS-PO'WELL BA, BRACIALE TJ: Recognition of an immunog,lobulin V11 epitope by influenza virus-specific class I major histocompatibility complex-re-stricted cytolytic T lymphocytes. J. Erp. Med. (1994) 179:195.
   PubMed Web of Science ®Google Scholar
• An influenza virus specific CTL cross-reacts with a CDR II epitope presented by a MOPC providing definitive evidence for T-cell recognition of idiotypic determinants presented myeloma, by B-cell tumors.
   Google Scholar
• KAWAMURA H, ROSENBERG SA, BERZOFSKY JA: Immu-nization with antigen and interleukin 2 in vivo over-comes Ir gene low responsiveness. I. Exp. Med. (1985) 162:381.
   PubMed Web of Science ®Google Scholar
• HUGHES HPA, CAMPOS M, GODSON DL, ET AL.: Immu-nopotentiation of bovine herpes virus subunit vaccina-tion by interleultin-2. Immunol. (1991) 164:188.
   Google Scholar
• NUNBERG JH, DOYLE MV, YORK SM, ETAL.: Interleukin-2 acts as an adjuvant to increase the potency of inacti-vated rabies virus vaccine. Proc. Natl. Acad. Sci. USA (1989) 86:4240.
   Google Scholar
• WEINBERG A, MERIGAN TC: Recombinant interleukin-2as an adjuvant for vaccine-induced protection. J. Immu-not. (1988) 140:294.
   PubMed Web of Science ®Google Scholar
• GOOD MF, POMBO D, LUNDE MN, ETAL.: Recombinanthuman 11,-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. J. Immuna (1988) 141:972.
   Google Scholar
• MEUER SC, DUMANN H, BUSCHENFELDE KHM, ET AL.: Low-dose interleukin-2 induces systemic immune re-sponses against HBsAg in immunodeficient nonre- sponders to hepatitis B vaccination. Lancet (1989)1:15. Use of IL-2 as a vaccine adjuvant in human patients.
   Google Scholar
• OFFIT K, CHAGANTI RSK: Chromosomal aberrations in non-Hodgkin's lymphoma: biologic and clinical corre-lations. Hematol. Oncol. Clin. North Am. (1991) 5:853.
   PubMed Web of Science ®Google Scholar
• MIZOGUCHU H, O'SHEA JJ, LONGO DL, ETAL.: Alterations In signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 258:1795.
   PubMed Web of Science ®Google Scholar
• TAO M-H, LEVY R: Idlotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 362:755.
   PubMed Web of Science ®Google Scholar
• KWAK LW, TAUB DD, DUFFEY PL, ETAL.: Transfer of myeloma idiotype-specific immunity from an activelyimunized allogeneic bone marrow donor. Blood (1993) 82\(Suppl 1):200a.
   Google Scholar
• First application of vaccination against idiotype to multiple myeloma.
   Google Scholar
• GATELY MK, WARRIER RR, HONASOGE S, ETAL.: Admini-stration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int. Imtnunol. (1994) 6:157.
   Google Scholar
• BRUNDA MJ, LUISTRO L, WARRIER RR, ETAL.: Antitumor and antimetastric activity of interleukin 12 against murine tumors. J. Exp. Med. (1993) 178:1223.
   Google Scholar
• GATELY MK, LUISTRO L, HENDRZAK JA, ET AL.: Inter-leukin-12: A cytokine with potent antimetastatic and antitumor activity in mice. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• HUANG AY, GOLUMBEK P, AHMADZADEH M, ETAL.: Roleof bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264:961.
   Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A, ETAL.: Vaccinationwith irradiated cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor Immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539.
   Google Scholar
• JAFEE EM, DRANOFF G, COHEN LK, ETAL.: High efficiencytransfer into primary human tumor explants without cell selection. Cancer Res. (1993) 53:2221.
   Google Scholar
• GOLUMBEK PT, ASHARI R, JAFEE EM, ETAL.: Controlledrelease, biodegradable cytokine depots: a new ap-proach in cancer vaccine design. Cancer Res. (1993) 53:5841.
   Google Scholar
• HARDING FA, ALLISON JP: CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. (1993) 177:1791.
   PubMed Web of Science ®Google Scholar
• ALLISON JP: Costimulation in tumor immunity. In: Pro-ceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• RESTIFO NP, IRVINE KR, BRONTE V, ETAL.: Recombinant vaccines in the treatment of established cancer. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• COHEN J: Cancer vaccines get a shot in the arm. Science (1993) 262:841.
   PubMed Web of Science ®Google Scholar
• GAUGLER B, VAN DEN EB, VAN DER BP, ETAL.: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. (1994) 179:921.
   PubMed Web of Science ®Google Scholar
• DE SMET C, LURQUIN C, VAN DER BP, ETAL.: Sequence and expression pattern of the human MAGE2 gene. Immunogenetics (1994) 39:121.
   Google Scholar
• BRICHARD V, VAN PEL A, WOLFEL T, ETAL.: The tyrosi-nase gene codes for an antigen recognized by autolo-gous cytolytic T lymphocytes on HIA-A2 melanomas. J. Exp. Med. (1993) 178:489.
   Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH, ETAL.: Cloning of the gene for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tu-mor. Proc. Natl. Acad. Sci. USA (1994) 91:3515.
   Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH, ETAL.: Identi-fication of a human melanoma antigen recognised by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA (1994) 91:6458.
   Google Scholar
• ROSENBERG SA: Cancer immunotherapy based on mela-noma antigens recognized by tumor infiltrating lym-phocytes. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• PARDOLL DM: New strategies in vaccine engineering. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• FELDMAN M, EISENBACH L, MANDELBOIM 0, ETAL.: Gene therapy and peptide therapy of tumor metastasis. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• MINEV BR, MCFARLAND BJ, SPIESS PJ, ETAL.: Insertion signal sequence fused to minimal peptides elicits spe-cific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. (1994) 54:4155.
   Google Scholar
• FELTKAMP MCW, SMITS HL, VIERBOOM MPM, ET AL.: Vaccination with cytotoxic T lymphocyte epitope-con-taining peptide protects against a tumor induced by human papilk:mavirus type 16-transformed cells. Eur. J. Immunol. (1993) 23:2242.
   Google Scholar
• MELIEF CJM: Anti tumor effects of vaccination with MHC class I binding peptides. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• GREY H: Development of a peptide based vaccine for the induction of CTL responses in man. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• CELIS E, TSAI V, CRIMI C, ETAL.: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using pri-mary cultures and synthetic peptide epitopes. Proc. NatL Acad. Sci. USA (1994) 91:2105.
   Google Scholar
• COX AL, SKIPPER J, CHEN Y, ET AL.: Identification of apeptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science (1994) 264:716.
   Google Scholar
• HUNT DF: Identification of processed antigens by tan-dem mass spectrometry. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar
• STORKUS WJ, ZEH HJ, MAEURER MJ, ET AL.: Identificationof human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunot (1993) 151:3719.
   Google Scholar
• FINN 0J: Epithelial tumor mudn-based immunity andcancer vacdnes. In: Proceedings of the Cancer Vaccines Symposium. New York, New York, October 3–5, 1994.
   Google Scholar